Apr 10, 2019 - Lilly (LLY) could produce exceptional returns because of its solid growth attributes.
Apr 09, 2019 - United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Apr 06, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Apr 05, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Apr 05, 2019 - The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
Apr 02, 2019 - AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.